Author:
Friedman Claire F.,D'Souza Anishka,Bello Roufai Diana,Tinker Anna V.,de Miguel Maria,Gambardella Valentina,Goldman Jonathan,Loi Sherene,Melisko Michelle E.,Oaknin Ana,Spanggaard Iben,Shapiro Geoffrey I.,ElNaggar Adam C.,Panni Stefano,Ravichandran Vignesh,Frazier Aimee L.,DiPrimeo Daniel,Eli Lisa D.,Solit David B.
Funder
Cycle for Survival
Marie-Josée and Henry R. Kravis Center for Molecular Oncology
Puma Biotechnology Inc
Subject
Obstetrics and Gynecology,Oncology
Reference40 articles.
1. Pembrolizumab for persistent, recurrent, or metastatic cervical Cancer;Colombo;N. Engl. J. Med.,2021
2. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study;Coleman;Lancet Oncol.,2021
3. Survival with cemiplimab in recurrent cervical cancer;Tewari;N. Engl. J. Med.,2022
4. HER kinase inhibition in patients with HER2- and HER3-mutant cancers;Hyman;Nature.,2018
5. Activating HER2 mutations as emerging targets in multiple solid cancers;Connell;ESMO Open.,2017